Dendritic cell immunotherapy for brain tumors

Journal of Neuro-Oncology

Volumn 123, Issue 3, 2015, Pages 425-432

  Antonios, Joseph P ^a   Everson, Richard G ^a   Liau, Linda M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dendritic cell vaccine; Glioblastoma; Glioma; Immunotherapy

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; BETA INTERFERON; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; DIPHTHERIA TETANUS TOXOID; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; OMEGA INTERFERON; PROGRAMMED DEATH 1 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA2; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ATYPICAL TERATOID RHABDOID TUMOR; CANCER IMMUNOTHERAPY; CANCER SURGERY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL MIGRATION; CELLULAR IMMUNITY; CONTRAST ENHANCEMENT; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MULTICENTER STUDY (TOPIC); NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TH2 CELL; TUMOR BIOPSY; TUMOR RECURRENCE; TUMOR VASCULARIZATION; VACCINATION; ANIMAL; BRAIN NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

ANIMALS; BRAIN NEOPLASMS; DENDRITIC CELLS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY;

EID: 84937524417     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1830-1     Document Type: Review

References (47)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
2. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674
3. Yamanaka R, Kajiwara K (2012) Dendritic cell vaccines. Adv Exp Med Biol 746:187–200
4. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM et al (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068
5. Trumpfheller C, Longhi MP, Caskey M, Idoyaga J, Bozzacco L, Keler T et al (2012) Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med 271:183–192
6. Steinman RM, Idoyaga J (2010) Features of the dendritic cell lineage. Immunol Rev 234:5–17
7. Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449:419–426
8. Shurin MR, Salter RD (2009) Dendritic cells in cancer. Springer, New York
9. Liu K, Nussenzweig MC (2010) Origin and development of dendritic cells. Immunol Rev 234:45–54
10. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ et al (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:5515–5525
11. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH et al (2011) Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17:1603–1615
12. Caruso DA, Orme LM, Neale AM, Radcliff FJ, Amor GM, Maixner W et al (2004) Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro-oncology 6:236–246
13. Tacken PJ, De Vries IJM, Torensma R, Figdor CG (2007) Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 7:790–802
14. Kalinski P, Okada H (2010) Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Semin Immunol 22(3):173–182
15. + T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic–polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29:330–336
16. Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L et al (2000) Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurg Focus 9:e8
17. Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B et al (2013) Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother 36:152–157
18. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK et al (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842–847
19. Polyzoidis S, Ashkan K (2014) DCVax(R)-L-developed by Northwest Biotherapeutics. Hum Vaccine Immunother 10:3139–3145
20. (+) CD8 T cells mediate beneficial anti-glioma immune responses. Cancer Immunol Immunother 63:911–924
21. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S et al (2008) Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68:5955–5964
22. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J et al (2008) Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14:3098–3104
23. Ardon H, De Vleeschouwer S, Van Calenbergh F, Claes L, Kramm CM, Rutkowski S et al (2010) Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer 54:519–525
24. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE II, Lally-Goss D et al (2009) An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 8:2773–2779
25. Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA et al (2012) Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 23:1043–1053
26. Cao JX, Zhang XY, Liu JL, Li D, Li JL, Liu YS et al (2014) Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis. PLoS ONE 9:e107173
27. Butowski N (2010) Immunostimulants for malignant gliomas. Neurosurg Clin N Am 21:53–65
28. Kamimura K, Suda T, Zhang G, Liu D (2011) Advances in gene delivery systems. Pharm Med 25:293–306
29. Rainov NG, Heidecke V (2011) Clinical development of experimental virus-mediated gene therapy for malignant glioma. Anti-cancer Agents Med Chem (Former Curr Med Chem Anti-cancer Agents) 11:739–747
30. Chiocca EA, Smith KM, McKinney B, Palmer CA, Rosenfeld S, Lillehei K et al (2008) A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther 16:618–626
31. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I (2011) Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 17:2619–2627
32. Pluhar GE, Grogan PT, Seiler C, Goulart M, SantaCruz KS, Carlson C et al (2010) Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine 28:3371–3378
33. Colombo F, Barzon L, Franchin E, Pacenti M, Pinna V, Danieli D et al (2005) Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther 12:835–848
34. Serre K, Mohr E, Gaspal F, Lane PJ, Bird R, Cunningham AF et al (2010) IL-4 directs both CD4 and CD8 T cells to produce Th2 cytokines in vitro, but only CD4 T cells produce these cytokines in response to alum-precipitated protein in vivo. Mol Immunol 47:1914–1922
35. Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejjani GK et al (2007) Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med 5:67
36. Sonabend AM, Velicu S, Ulasov IV, Han Y, Tyler B, Brem H et al (2008) A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma. Anticancer Drugs 19:133–142
37. Mitchell DA, Batich KA, Gunn MD, Huang M-N, Sanchez-Perez L, Nair SK et al (2015) Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519:366–369
38. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295–307
39. Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19:5300–5309
40. Fong B, Jin R, Wang X, Safaee M, Lisiero DN, Yang I et al (2012) Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS ONE 7:e32614
41. Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144
42. Curran MA, Montalvo W, Yagita H, Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107:4275–4280
43. Schartner JM, Hagar AR, Van Handel M, Zhang L, Nadkarni N, Badie B (2005) Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia 51:279–285
44. Grauer O, Pschl P, Lohmeier A, Adema GJ, Bogdahn U (2007) Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2. J Neurooncol 82:151–161
45. Ribas A (2012) Tumor immunotherapy directed at PD-1. N Engl J Med 366:2517–2519
46. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J et al (2013) Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86:343–349
47. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim C, Tobias AL et al (2014) Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors. Clin Cancer Res 20(20):5290–5301